Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
Investors 1
Mentions in press and media 2
| Date | Title | Description |
| 25.04.2025 | Granite Bio debuts with $100 million to tackle autoimmune diseases |
Granite Bio is a biotechnology company developing first-in-class antibodies that target the root causes of a variety of inflammatory, autoimmune and fibrotic conditions. Its pipeline comprises two lead candidates. GRT-001 depletes pro-infl... |
| - | Granite Bio | “Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.” |
Reviews 0
